Herold Advisors Inc. Sells 1,033 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Herold Advisors Inc. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 7,288 shares of the biopharmaceutical company’s stock after selling 1,033 shares during the period. Herold Advisors Inc.’s holdings in Gilead Sciences were worth $591,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Morgan Stanley raised its position in Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after purchasing an additional 158,794 shares in the last quarter. Northern Trust Corp raised its position in Gilead Sciences by 3.5% during the 3rd quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock valued at $1,118,291,000 after purchasing an additional 504,475 shares in the last quarter. Pacer Advisors Inc. raised its position in Gilead Sciences by 10.8% during the 4th quarter. Pacer Advisors Inc. now owns 5,046,652 shares of the biopharmaceutical company’s stock valued at $408,829,000 after purchasing an additional 493,920 shares in the last quarter. AQR Capital Management LLC raised its position in Gilead Sciences by 12.5% during the 3rd quarter. AQR Capital Management LLC now owns 4,773,688 shares of the biopharmaceutical company’s stock valued at $357,740,000 after purchasing an additional 531,314 shares in the last quarter. Finally, Clearbridge Investments LLC raised its position in Gilead Sciences by 179.0% during the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after purchasing an additional 2,915,141 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. UBS Group reduced their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. TD Cowen reduced their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank of Canada reduced their price target on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research report on Friday. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Finally, Morgan Stanley reduced their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday. Eleven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average target price of $83.87.

Gilead Sciences Stock Performance

Gilead Sciences stock traded up $0.15 during trading hours on Friday, hitting $65.42. 12,349,126 shares of the stock traded hands, compared to its average volume of 7,477,028. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm’s 50 day moving average price is $71.28 and its 200-day moving average price is $76.25. The stock has a market capitalization of $81.45 billion, a price-to-earnings ratio of 14.54, a P/E/G ratio of 1.20 and a beta of 0.19. Gilead Sciences, Inc. has a 1 year low of $64.63 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.37 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.2 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.71%. The ex-dividend date was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is presently 68.44%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.